Chromatin and immune regulation of tumor growth and progression
肿瘤生长和进展的染色质和免疫调节
基本信息
- 批准号:10744436
- 负责人:
- 金额:$ 4.92万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2023
- 资助国家:美国
- 起止时间:2023-08-10 至 2025-07-31
- 项目状态:未结题
- 来源:
- 关键词:3-DimensionalAntigensArchitectureBar CodesBiological AssayBiological ProcessCellsCellular ImmunityCharacteristicsChromatinChromatin LoopChromosome MappingComplexCytotoxic T-LymphocytesDataDedicationsDependenceDevelopmentDiagnosisDisease ProgressionEvolutionGene ExpressionGene Expression ProfileGene Expression ProfilingGenesGeneticGenetically Engineered MouseGoalsImmune EvasionImmune responseImmunophenotypingKRAS oncogenesisKRAS2 geneLaboratoriesLungLung NeoplasmsMaintenanceMalignant neoplasm of lungMalignant neoplasm of pancreasMediatingMediatorMentorsMethodologyMolecularMolecular ConformationMusPancreatic Ductal AdenocarcinomaPhasePlayPositioning AttributePostdoctoral FellowProteinsRegulationResearchResearch Project GrantsRoleShapesSystemT cell responseT-LymphocyteTechniquesTimeTrainingTumor ImmunityTumor SubtypeTumor SuppressionTumor Suppressor GenesTumor Suppressor ProteinsTumor VolumeTumor stageWorkanti-tumor immune responsecancer cellcancer typecandidate identificationcell typechemotherapycohesinexperienceexperimental studyfunctional genomicsgene functionhigh throughput screeningimmunoregulationin vivoinnovationinsightlung cancer celllung tumorigenesismedical specialtiesmouse modelmultidisciplinarymultiple omicsneoplastic cellnovelnovel strategiespancreatic ductal adenocarcinoma modelresponsetumortumor growthtumor heterogeneitytumor immunologytumor progressiontumorigenesis
项目摘要
PROJECT SUMMARY
Lung and pancreatic ductal adenocarcinomas are often diagnosed at very late stages of tumor progression when
they are most aggressive and difficult to treat. Currently, very little is known about the characteristics that make
up the complex tumor heterogeneity of late-stage tumors and what factors contribute to such changes in cancer
cell state and disease progression over time. Investigating how the mechanisms by which these contributing
factors impact tumorigenesis and tumor heterogeneity may uncover unappreciated biological processes that
control tumor development. The goal of this work is to elucidate the molecular and cellular mechanisms that
drive changes in chromatin state and immune response and how they shape tumor heterogeneity and tumor
progression. In the F99 phase, I aim to elucidate how a novel tumor suppressor gene constrains lung
tumorigenesis. My colleagues and I identified STAG2 as a tumor suppressor in a genetically engineered mouse
model of oncogenic KRAS-driven lung cancer. STAG2 is a subunit of one of the two major cohesin complexes,
which are implicated in regulating chromatin boundaries and gene expression. However, the mechanism by
which Stag2 inactivation drives lung tumor growth is unknown. I performed chromatin accessibility profiling and
gene expression analyses on STAG2-proficient and STAG2-deficient mouse lung cancer cells and have unveiled
potential mediators of STAG2 function. Based on my analyses, I hypothesize that STAG2 controls genes
involved in early stages of tumorigenesis by directly impacting cohesin regulation of 3D chromatin organization.
Using chromatin conformation assays, I will assess how STAG2 regulates chromatin at different stages of tumor
progression and how Stag2 inactivation drives lung tumorigenesis. Additionally, I will use Tuba-seq to identify
key epistatic and downstream mediators of STAG2 tumor suppression and chromatin conformation assays to
ascertain the STAG2-mediated mechanisms impacting lung tumor maintenance. In the K00 phase, I aim to
elucidate how cancer cell state shapes pancreatic ductal adenocarcinoma (PDAC) response to T-cell mediated
anti-tumor immunity. PDAC subpopulations with distinct transcriptional profiles, stromal composition, and
response to chemotherapy have been previously established. However, it remains unknown whether these tumor
subtypes harbor differential response to T-cell mediated immunity. To investigate how cancer cell state shapes
PDAC progression by enabling evasion of cytotoxic T cell responses, I will leverage PDAC mouse models that
enable the initiation of cytotoxic T cell responses at different stages of tumor progression using an inducible
mouse model T cell antigen. Using longitudinal multi-omics, immunophenotyping, and tumor volume analyses, I
will investigate how aspects of tumor heterogeneity contribute to mechanisms of immune evasion at various
stages of tumor progression, identify key mechanistic drivers, and thus uncover novel strategies to enhance anti-
tumor immune responses. Together, this body of work will elucidate principles of chromatin regulation and tumor
heterogeneity that contribute to progression and immune response in lung and pancreas cancers.
项目总结
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Emily Lorin Ashkin其他文献
Emily Lorin Ashkin的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
相似国自然基金
Neo-antigens暴露对肾移植术后体液性排斥反应的影响及其机制研究
- 批准号:2022J011295
- 批准年份:2022
- 资助金额:10.0 万元
- 项目类别:省市级项目
结核分枝杆菌持续感染期抗原(latency antigens)的重组BCG疫苗研究
- 批准号:30801055
- 批准年份:2008
- 资助金额:19.0 万元
- 项目类别:青年科学基金项目
相似海外基金
Bovine herpesvirus 4 as a vaccine platform for African swine fever virus antigens in pigs
牛疱疹病毒 4 作为猪非洲猪瘟病毒抗原的疫苗平台
- 批准号:
BB/Y006224/1 - 财政年份:2024
- 资助金额:
$ 4.92万 - 项目类别:
Research Grant
A novel vaccine approach combining mosquito salivary antigens and viral antigens to protect against Zika, chikungunya and other arboviral infections.
一种结合蚊子唾液抗原和病毒抗原的新型疫苗方法,可预防寨卡病毒、基孔肯雅热和其他虫媒病毒感染。
- 批准号:
10083718 - 财政年份:2023
- 资助金额:
$ 4.92万 - 项目类别:
Small Business Research Initiative
Uncovering tumor specific antigens and vulnerabilities in ETP-acute lymphoblastic leukemia
揭示 ETP-急性淋巴细胞白血病的肿瘤特异性抗原和脆弱性
- 批准号:
480030 - 财政年份:2023
- 资助金额:
$ 4.92万 - 项目类别:
Operating Grants
Regulation of B cell responses to vaccines by long-term retention of antigens in germinal centres
通过在生发中心长期保留抗原来调节 B 细胞对疫苗的反应
- 批准号:
MR/X009254/1 - 财政年份:2023
- 资助金额:
$ 4.92万 - 项目类别:
Research Grant
Adaptive Discrimination of Risk of Antigens in Immune Memory Dynamics
免疫记忆动态中抗原风险的适应性辨别
- 批准号:
22KJ1758 - 财政年份:2023
- 资助金额:
$ 4.92万 - 项目类别:
Grant-in-Aid for JSPS Fellows
22-ICRAD Call 2 - Improving the diagnosis of tuberculosis in domestic ruminants through the use of new antigens and test platforms
22-ICRAD 呼吁 2 - 通过使用新抗原和测试平台改善家养反刍动物结核病的诊断
- 批准号:
BB/Y000927/1 - 财政年份:2023
- 资助金额:
$ 4.92万 - 项目类别:
Research Grant
Protective immunity elicited by distinct polysaccharide antigens of classical and hypervirulent Klebsiella
经典和高毒力克雷伯氏菌的不同多糖抗原引发的保护性免疫
- 批准号:
10795212 - 财政年份:2023
- 资助金额:
$ 4.92万 - 项目类别:
Integrative proteome analysis to harness humoral immune response against tumor antigens
综合蛋白质组分析利用针对肿瘤抗原的体液免疫反应
- 批准号:
23K18249 - 财政年份:2023
- 资助金额:
$ 4.92万 - 项目类别:
Grant-in-Aid for Challenging Research (Exploratory)
Functionally distinct human CD4 T cell responses to novel evolutionarily selected M. tuberculosis antigens
功能独特的人类 CD4 T 细胞对新型进化选择的结核分枝杆菌抗原的反应
- 批准号:
10735075 - 财政年份:2023
- 资助金额:
$ 4.92万 - 项目类别:
Targeting T3SA proteins as protective antigens against Yersinia
将 T3SA 蛋白作为针对耶尔森氏菌的保护性抗原
- 批准号:
10645989 - 财政年份:2023
- 资助金额:
$ 4.92万 - 项目类别: